Safety, tolerability, pharmacokinetics and antitumor activity of ganitumab, an investigational fully human monoclonal antibody to insulin-like growth factor type 1 receptor, combined with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer: A phase 1b study

Japanese Journal of Clinical Oncology

Volumn 44, Issue 5, 2014, Pages 442-447

  Okusaka, Takuji ^a   Ikeda, Masafumi ^b   Fukutomi, Akira ^c   Kobayashi, Yoshikazu ^d   Shibayama, Kazuhiro ^d   Takubo, Takatoshi ^d   Gansert, Jennifer ^e  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c SHIZUOKA CANCER CENTER   (Japan)

^d Takeda Bio Development Center Ltd   (Japan)

^e AMGEN INC   (United States)

Author keywords

Clinical trial Phase 1; Ganitumab; Gemcitabine; Pancreatic neoplasms; Receptor, insulin like growth factor type 1

Indexed keywords

GANITUMAB; GEMCITABINE; INSULIN LIKE GROWTH FACTOR TYPE 1 RECEPTOR; SOMATOMEDIN RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; NEW DRUG; SOMATOMEDIN C RECEPTOR;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER PAIN; CANCER PATIENT; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EXPOSURE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HYPERGLYCEMIA; INFUSION RELATED REACTION; LEUKOPENIA; LUNG EMBOLISM; MALE; NAUSEA; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; PANCREAS METASTASIS; PHASE 1 CLINICAL TRIAL; RASH; THROMBOCYTOPENIA; TREATMENT DURATION; VASCULAR DISEASE; VOMITING; ADENOCARCINOMA; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL PHASE 1; DRUG ADMINISTRATION; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; METASTASIS; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; RECEPTOR, INSULIN-LIKE GROWTH FACTOR TYPE 1; TREATMENT OUTCOME;

CLINICAL TRIAL PHASE 1; GANITUMAB; GEMCITABINE; PANCREATIC NEOPLASMS; RECEPTOR, INSULIN-LIKE GROWTH FACTOR TYPE 1;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUGS, INVESTIGATIONAL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKOPENIA; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RECEPTOR, IGF TYPE 1; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84902273066     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyu034     Document Type: Article

References (15)

1. Weroha SJ, Haluska P. IGF-1 receptor inhibitors in clinical trials-early lessons. J Mammary Gland Biol Neoplasia 2008;13:471-83.
2. Werner H, LeRoith D. The role of the insulin-like growth factor system in human cancer. Adv Cancer Res 1996;68:183-223.
3. Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 2007;6:1-12.
4. Macaulay VM. Insulin-like growth factors and cancer. Br J Cancer 1992;65:311-20.
5. Werner H, Le Roith D. New concepts in regulation and function of the insulin-like growth factors: implications for understanding normal growth and neoplasia. Cell Mol Life Sci 2000;57:932-42.
6. Ryan PD, Goss PE. The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist 2008;13:16-24.
7. Beltran PJ, Mitchell P, Chung YA, et al. AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol Cancer Ther 2009;8:1095-105.
8. Tolcher AW, Sarantopoulos J, Patnaik A, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009;27:5800-7.
9. Murakami H, Doi T, Yamamoto N, et al. Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF 1R), in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2012;70:407-14.
10. Kindler HL, Richards DA, Garbo LE, et al. A randomized, placebocontrolled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol 2012;23:2834-42.
11. Lu JF, Deng H, Tang R, et al. Exposure-response analysis to facilitate phase 3 dose selection for ganitumab (AMG 479) in combination with gemcitabine to treat metastatic pancreatic cancer. ASCO 47th Annual Meeting, Chicago, IL, June 3-7, abstract 4049, 2011.
12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 2000;92:205-16.
13. Okada S, Ueno H, Okusaka T, Ikeda M, Furuse J, Maru Y. Phase I trial of gemcitabine in patients with advanced pancreatic cancer. Jpn J Clin Oncol 2001;31:7-12.
14. Scagliotti GV, Novello S. The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors. Cancer Treat Rev 2012;38:292-302.
15. Barrenäs M, Landin-Wilhelmsen K, Hanson C. Ear and hearing in relation to genotype and growth in Turner syndrome. Hear Res 2000;144:21-8.